Chronic orexin-A (hypocretin-1) treatment of type 2 diabetic rats improves glucose control and beta-cell functions

Area of Science:

• Endocrinology
• Metabolic Diseases
• Neuroscience

Background:

• Orexin is a neuropeptide hormone involved in regulating food intake and energy expenditure.
• Type 2 diabetes is characterized by impaired glucose regulation and insulin resistance.
• Orexin-A (OXA) is a specific form of orexin that has shown potential in metabolic regulation.

Purpose of the Study:

• To investigate the efficacy of orexin-A (OXA) in improving metabolic control in a rat model of type 2 diabetes.
• To elucidate the underlying mechanisms by which OXA exerts its effects on glucose homeostasis and pancreatic beta-cell function.

Main Methods:

• Type 2 diabetes was induced in rats using streptozotocin and a high-fat diet.
• Rats were chronically infused with OXA, and metabolic parameters were assessed.
• In vitro studies were performed on isolated pancreatic islets, primary adipocytes, and INS-1E cells to examine cellular mechanisms.

Main Results:

• OXA treatment significantly improved glucose control and enhanced insulin sensitivity in diabetic rats.
• OXA attenuated pancreatic beta-cell loss and improved glucose-stimulated insulin secretion in isolated islets.
• OXA reduced plasma levels of tumor necrosis factor-alpha (TNF-α) and non-esterified fatty acids (NEFA).
• OXA decreased palmitate- and TNF-α-induced apoptosis in INS-1E cells.

Conclusions:

• Orexin-A (OXA) demonstrates therapeutic potential for type 2 diabetes by improving glucose control and insulin sensitivity.
• OXA protects pancreatic beta cells from apoptosis, preserving their function.
• The beneficial effects of OXA may be mediated through the reduction of inflammatory factors like TNF-α and free fatty acids.